Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$39.23 +0.69 (+1.79%)
Closing price 03:59 PM Eastern
Extended Trading
$39.15 -0.08 (-0.20%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TEVA vs. ABBV, NVO, PFE, BMY, and SNY

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? Teva Pharmaceutical Industries's main competitors and comparable companies include AbbVie (ABBV), Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), and Sanofi (SNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Teva Pharmaceutical Industries compare to AbbVie?

Teva Pharmaceutical Industries (NYSE:TEVA) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

AbbVie has higher revenue and earnings than Teva Pharmaceutical Industries. AbbVie is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.60$1.41B$0.4389.60
AbbVie$61.16B8.19$4.23B$5.8148.77

AbbVie has a net margin of 15.67% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Teva Pharmaceutical Industries' return on equity of 33.20% beat AbbVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries2.94% 33.20% 6.59%
AbbVie 15.67%-450.55%16.50%

Teva Pharmaceutical Industries presently has a consensus target price of $48.64, suggesting a potential upside of 26.25%. AbbVie has a consensus target price of $299.62, suggesting a potential upside of 5.74%. Given Teva Pharmaceutical Industries' higher possible upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than AbbVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81
AbbVie
0 Sell rating(s)
6 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.83

Teva Pharmaceutical Industries has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

In the previous week, AbbVie had 4 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 32 mentions for AbbVie and 28 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.72 beat AbbVie's score of 0.66 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
14 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AbbVie
20 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
3 Very Negative mention(s)
Positive

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbbVie beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Novo Nordisk A/S?

Teva Pharmaceutical Industries (NYSE:TEVA) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Novo Nordisk A/S has higher revenue and earnings than Teva Pharmaceutical Industries. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.60$1.41B$0.4389.60
Novo Nordisk A/S$46.80B3.71$15.51B$3.979.80

In the previous week, Novo Nordisk A/S had 5 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 33 mentions for Novo Nordisk A/S and 28 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.72 beat Novo Nordisk A/S's score of 0.38 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
14 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
13 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
4 Negative mention(s)
4 Very Negative mention(s)
Neutral

Teva Pharmaceutical Industries has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Teva Pharmaceutical Industries presently has a consensus price target of $48.64, suggesting a potential upside of 26.25%. Novo Nordisk A/S has a consensus price target of $59.44, suggesting a potential upside of 52.84%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81
Novo Nordisk A/S
5 Sell rating(s)
16 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.00

Novo Nordisk A/S has a net margin of 33.99% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Novo Nordisk A/S's return on equity of 53.52% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries2.94% 33.20% 6.59%
Novo Nordisk A/S 33.99%53.52%19.49%

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Teva Pharmaceutical Industries on 9 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Pfizer?

Pfizer (NYSE:PFE) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Pfizer has higher revenue and earnings than Teva Pharmaceutical Industries. Pfizer is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$62.58B2.51$7.77B$0.7039.38
Teva Pharmaceutical Industries$17.26B2.60$1.41B$0.4389.60

68.4% of Pfizer shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pfizer has a net margin of 6.34% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Teva Pharmaceutical Industries' return on equity of 33.20% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer6.34% 19.88% 8.52%
Teva Pharmaceutical Industries 2.94%33.20%6.59%

Pfizer has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Pfizer currently has a consensus target price of $30.32, suggesting a potential upside of 9.98%. Teva Pharmaceutical Industries has a consensus target price of $48.64, suggesting a potential upside of 26.25%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81

In the previous week, Pfizer had 18 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 46 mentions for Pfizer and 28 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.72 beat Pfizer's score of 0.35 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
14 Very Positive mention(s)
10 Positive mention(s)
15 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
14 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Pfizer and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Bristol Myers Squibb presently has a consensus price target of $65.46, suggesting a potential upside of 12.23%. Teva Pharmaceutical Industries has a consensus price target of $48.64, suggesting a potential upside of 26.25%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Bristol Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
1 Sell rating(s)
16 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.47
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81

Bristol Myers Squibb has a net margin of 18.47% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Bristol Myers Squibb's return on equity of 60.48% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb18.47% 60.48% 14.45%
Teva Pharmaceutical Industries 2.94%33.20%6.59%

In the previous week, Bristol Myers Squibb had 18 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 46 mentions for Bristol Myers Squibb and 28 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.72 beat Bristol Myers Squibb's score of 0.26 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
12 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
14 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bristol Myers Squibb has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Bristol Myers Squibb has higher revenue and earnings than Teva Pharmaceutical Industries. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.19B2.47$7.05B$4.5112.93
Teva Pharmaceutical Industries$17.26B2.60$1.41B$0.4389.60

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Bristol Myers Squibb beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Sanofi?

Sanofi (NASDAQ:SNY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Sanofi currently has a consensus target price of $53.00, indicating a potential upside of 15.07%. Teva Pharmaceutical Industries has a consensus target price of $48.64, indicating a potential upside of 26.25%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.48
Teva Pharmaceutical Industries
1 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.81

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than Sanofi. MarketBeat recorded 28 mentions for Teva Pharmaceutical Industries and 19 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 0.72 beat Sanofi's score of 0.51 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
6 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
14 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi has a net margin of 8.70% compared to Teva Pharmaceutical Industries' net margin of 2.94%. Teva Pharmaceutical Industries' return on equity of 33.20% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi8.70% 15.16% 8.48%
Teva Pharmaceutical Industries 2.94%33.20%6.59%

Sanofi has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$49.35B2.26$8.84B$2.0222.80
Teva Pharmaceutical Industries$17.26B2.60$1.41B$0.4389.60

Summary

Teva Pharmaceutical Industries beats Sanofi on 10 of the 17 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

MetricTeva Pharmaceutical IndustriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$49.61B$13.61B$7.77B$21.76B
Dividend YieldN/A2.58%2.47%3.83%
P/E Ratio18.8425.9631.9823.89
Price / Sales2.656.788.103.50
Price / Cash11.4115.6321.0115.54
Price / Book5.735.164.263.45
Net Income$1.41B$2.86B$3.50B$1.07B
7 Day Performance-11.88%-7.23%-7.93%-7.11%
1 Month Performance-3.95%-9.61%-10.46%-7.16%
1 Year Performance61.46%-8.11%-2.79%2.58%

Teva Pharmaceutical Industries Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
4.3004 of 5 stars
$39.23
+1.8%
$48.64
+24.0%
+57.8%$49.61B$17.26B18.8433,950
ABBV
AbbVie
4.3112 of 5 stars
$294.18
-0.3%
$297.85
+1.2%
+21.5%$520.47B$61.16B22.9557,000
NVO
Novo Nordisk A/S
3.8627 of 5 stars
$41.60
-0.1%
$59.44
+42.9%
-20.7%$181.50B$46.80B10.4569,505
PFE
Pfizer
3.5701 of 5 stars
$28.84
-0.2%
$30.32
+5.1%
+10.6%$164.33B$62.58B9.4575,000
BMY
Bristol Myers Squibb
4.841 of 5 stars
$62.96
-0.7%
$65.46
+4.0%
+27.4%$127.39B$48.19B10.0032,500

Related Companies and Tools


This page (NYSE:TEVA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners